
Get exclusive money-saving offers and guides
Straight to your inbox
Updated
We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Clinuvel Pharmaceuticals Limited is a biotechnology business based in Australia. Clinuvel Pharmaceuticals shares (CUV) are listed on the Australian Securities Exchange (ASX) and all prices are listed in Australian Dollars. Clinuvel Pharmaceuticals has a trailing 12-month revenue of around $32.6 million.
Our top pick for
US stocks
Our top pick for
Cheap broker fees
Our top pick for
Long-term investing
Since the stock market crash in March caused by coronavirus, Clinuvel Pharmaceuticals's share price has had significant negative movement.
Its last market close was $22, which is 12.21% down on its pre-crash value of $25.06 and 70.28% up on the lowest point reached during the March crash when the shares fell as low as $12.92.
If you had bought $1,000 worth of Clinuvel Pharmaceuticals shares at the start of February 2020, those shares would have been worth $578.83 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $828.52.
52-week range | $12.9043 - $29.8138 |
---|---|
50-day moving average | $21.7479 |
200-day moving average | $22.2629 |
Target price | $32.7 |
PE ratio | 63.7576 |
Dividend yield | $0.03 (0.12%) |
Earnings per share (TTM) | $0.33 |
Standard brokerage - Australian shares
Competitive broker fees on Australian and international shares
Important: Share trading carries risk of capital loss.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the close of A$22 on 2020-10-22
1 week (2021-01-08) | 5.77% |
---|---|
1 month (2020-12-16) | -2.91% |
3 months (2020-10-16) | -2.83% |
6 months (2020-07-16) | -5.13% |
1 year (2020-01-15) | -24.94% |
---|---|
2 years (2019-01-15) | 0.69% |
3 years (2018-01-15) | 147.19% |
5 years (2016-01-15) | 671.93% |
Valuing Clinuvel Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Clinuvel Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Clinuvel Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 64x. In other words, Clinuvel Pharmaceuticals shares trade at around 64x recent earnings.
That's relatively high compared to, say, the P/E ratio for the ASX over the 12 months to December 2019 (32.14). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Clinuvel Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $12 million (£0.0 million).
The EBITDA is a measure of a Clinuvel Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.
Revenue TTM | $32.6 million |
---|---|
Operating margin TTM | 36.29% |
Gross profit TTM | $30.4 million |
Return on assets TTM | 10.27% |
Return on equity TTM | 25.44% |
Profit margin | 51.12% |
Book value | 1.491 |
Market capitalisation | $1 billion |
TTM: trailing 12 months
Dividend payout ratio: 7.81% of net profits
Recently Clinuvel Pharmaceuticals has paid out, on average, around 7.81% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.12% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Clinuvel Pharmaceuticals shareholders could enjoy a 0.12% return on their shares, in the form of dividend payments. In Clinuvel Pharmaceuticals's case, that would currently equate to about A$0.03 per share.
While Clinuvel Pharmaceuticals's payout ratio might seem low, this can signify that Clinuvel Pharmaceuticals is investing more in its future growth.
The latest dividend was paid out to all shareholders who bought their shares by 3 September 2020 (the "ex-dividend date").
Clinuvel Pharmaceuticals's shares were split on a 1:10 basis on 12 November 2010. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Clinuvel Pharmaceuticals shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Clinuvel Pharmaceuticals shares which in turn could have impacted Clinuvel Pharmaceuticals's share price.
Over the last 12 months, Clinuvel Pharmaceuticals's shares have ranged in value from as little as $12.9043 up to $29.8138. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while Clinuvel Pharmaceuticals's is 0.3907. This would suggest that Clinuvel Pharmaceuticals's shares are less volatile than average (for this exchange).
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and delivering drugs for the treatment of patients with severe genetic and skin disorders worldwide. Its lead drug candidate is SCENESSE, a photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), an addition to the family of melanocortin analogues, which provoke increased and prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited for launching SCENESSE under a named patient program for the treatment of patients with EPP in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.
Steps to owning and managing Vanguard Australian Fixed Interest Index ETF units.
Steps to owning and managing Vanguard Ethically Conscious Global Aggregate Bond Index (Hedged) ETF units.
Steps to owning and managing ETFS Morningstar Global Technology ETF units.
Steps to owning and managing BetaShares Global Quality Leaders (Currency Hedged) ETF units.
Steps to owning and managing ETFS ROBO Global Robotics and Automation ETF units.
Steps to owning and managing ETFS FANG+ ETF units.
Steps to owning and managing ETFS S&P Biotech ETF units.
Steps to owning and managing ETFS Reliance India Nifty 50 ETF units.
Steps to owning and managing BetaShares India Quality ETF units.